Teleflex Incorporated ($TFX) Stock Forecast: Up 3.6% Today

What is Teleflex Incorporated?

Teleflex Inc. (TFX) is a global provider of single-use medical technology products, specializing in critical medical devices like vascular access and interventional tools. The company has a strong balance sheet, robust innovation pipeline, and consistent revenue streams from essential procedures.

Why is Teleflex Incorporated going up?

TFX stock is up 3.6% on Apr 16, 2026 19:51

• TFX stock experienced a strong bullish movement, rising 1.65% to $125.21, outperforming the broader market indices.
• The bullish trend can be attributed to a price target increase on TFX to $135 from $125, indicating confidence in the company's performance and growth prospects.
• Despite missing Q4 earnings expectations and reporting a revenue decline, TFX's focus on specialized products, global footprint, and commitment to innovation have positioned it as a defensive play in the healthcare sector, appealing to investors seeking reliable growth.
• The positive performance of TFX amidst a general uplift in the stock market reflects investor confidence in the company's market leadership and potential for steady shareholder returns.

TFX Price Chart

TFX Technical Analysis

TFX News

Vascular Closure Devices Market Set for Steady Growth at 5.70% CAGR Through 2032: DelveInsight | Abbott, Teleflex, and Medtronic

The global vascular closure devices market is expected to grow from USD 1,548.87 million in 2024 to USD 2,398.52 million by 2032, exhibiting a CAGR of 5.70% during the forecast period. This growth is primarily driven by the increasing prevalence of cardiovascular diseases, the rising adoption of minimally invasive procedures, and continuous technological advancements. North America is anticipated to lead the market, while Asia-Pacific is projected to be the fastest-growing region.

https://www.barchart.com/story/news/1330808/vascular-closure-devices-market-set-for-steady-growth-at-570-cagr-through-2032-delveinsight-abbott-teleflex-and-medtronic

Teleflex Inc stock (US8793691069): Why its medical device leadership matters more now for investors

Teleflex Inc. specializes in critical medical devices like vascular access and interventional tools, appealing to investors seeking reliable growth in healthcare. The company boasts a strong balance sheet, a robust innovation pipeline, and consistent revenue streams from essential procedures, making it a defensive play in a volatile market. Teleflex's focus on specialized products, global footprint, and commitment to innovation positions it for continued market leadership and steady shareholder returns.

https://www.ad-hoc-news.de/boerse/ueberblick/teleflex-inc-stock-us8793691069-why-its-medical-device-leadership/69152473

Teleflex Inc. stock outperforms competitors on strong trading day

Teleflex Inc. (TFX) shares rose 1.65% to $125.21 on a strong trading day, outpacing the broader market indices like the S&P 500 and Dow Jones Industrial Average. This marks the second consecutive day of gains for the company's stock. The positive performance occurred amidst a general uplift in the stock market.

https://www.marketwatch.com/data-news/teleflex-inc-stock-outperforms-competitors-on-strong-trading-day-c253b2d2-00f86664ebfa

RBC Raises Price Target on Teleflex to $135 From $125, Keeps Sector Perform Rating

RBC Capital has increased its price target for Teleflex Incorporated (TFX) to $135, up from $125, while maintaining a "Sector Perform" rating on the stock. This adjustment comes amidst recent company news including board changes and plans for share buybacks. Teleflex is a global provider of single-use medical technology products.

https://www.marketscreener.com/news/rbc-raises-price-target-on-teleflex-to-135-from-125-keeps-sector-perform-rating-ce7e50dfd881ff23

Teleflex Incorporated (NYSE:TFX) Given Consensus Rating of "Hold" by Analysts

Analysts have given Teleflex Incorporated (NYSE:TFX) a consensus "Hold" rating, with an average 12-month price target of $138.50. This comes after Teleflex significantly missed Q4 earnings expectations, reporting an EPS of $1.93 against an anticipated $3.73 and a 28.5% year-over-year revenue decline. Despite institutional ownership by 95.62% of investors and a quarterly dividend of $0.34, the company's financial metrics reflect recent earnings weakness, leading to a negative payout ratio and P/E.

https://www.marketbeat.com/instant-alerts/teleflex-incorporated-nysetfx-given-consensus-rating-of-hold-by-analysts-2026-04-14/

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.1% Today

General Electric Company ($GE) Stock Forecast: Down 5.0% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 5.0% Today

Teleflex Incorporated ($TFX) Stock Forecast: Up 3.6% Today

Hewlett Packard Enterprise Company ($HPE) Stock Forecast: Up 5.3% Today

C.H. Robinson Worldwide Inc. ($CHRW) Stock Forecast: Up 8.4% Today

Albemarle Corporation ($ALB) Stock Forecast: Up 15.0% Today

Charles Schwab Corporation (The) ($SCHW) Stock Forecast: Down 7.4% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.6% Today

Charter Communications Inc. ($CHTR) Stock Forecast: Up 5.4% Today

Teleflex Incorporated Price History

09.11.2025 - TFX Stock was up 8.8%

• The bullish movement in TFX may be linked to a theory emphasizing the company's strategic turnaround and potential upside.
• An analysis suggests TFX could be undervalued by up to 74.2%, sparking investor interest and increased buying activity.
• The recent acquisition of BIOTRONIK's Vascular Intervention business and positive FY 2025 EPS guidance by the company likely contributed to the bullish momentum.
• Despite concerns from analysts lowering price targets and ratings, the overall positive outlook on TFX's growth prospects and strategic initiatives appears to have driven the stock higher.

09.11.2025 - TFX Stock was up 10.4%

• The bullish movement in TFX stock today can be attributed to the completion of the $2.03 billion sale of its Acute Care, Interventional Urology, and OEM businesses. This strategic divestiture is part of Teleflex's plan to optimize its portfolio and focus on core markets, which has likely been well-received by investors.
• The sale will provide Teleflex with approximately $1.8 billion in net proceeds, which the company plans to utilize for returning capital to shareholders through share repurchases and paying down debt. This capital allocation strategy could be seen as a positive signal by investors, driving up the stock price.
• The acquisition of Teleflex Medical OEM by private equity firms Montagu and Kohlberg for $1.5 billion is also a significant development. This move is expected to position Teleflex Medical OEM as an independent global contract developer and manufacturer, potentially unlocking new growth opportunities and enhancing innovation capabilities.
• Overall, the market seems to be reacting positively to Teleflex's strategic initiatives and the potential for accelerated growth and value creation following the divestiture and acquisition deals.

16.03.2026 - TFX Stock was up 3.6%

• TFX stock experienced a strong bullish movement, rising 1.65% to $125.21, outperforming the broader market indices.
• The bullish trend can be attributed to a price target increase on TFX to $135 from $125, indicating confidence in the company's performance and growth prospects.
• Despite missing Q4 earnings expectations and reporting a revenue decline, TFX's focus on specialized products, global footprint, and commitment to innovation have positioned it as a defensive play in the healthcare sector, appealing to investors seeking reliable growth.
• The positive performance of TFX amidst a general uplift in the stock market reflects investor confidence in the company's market leadership and potential for steady shareholder returns.

08.00.2026 - TFX Stock was down 11.7%

• The decrease in TFX stock value today could be linked to an average "Reduce" rating provided by twelve analysts, signaling cautious predictions about the company's future performance.
• Despite posting strong Q3 earnings and optimistic forecasts for FY2025, the market seems to have reacted negatively to the rating downgrade.
• Investor apprehension about potential obstacles or challenges that could hinder Teleflex's growth trajectory could explain the downward trend in the stock price.
• Uncertainties surrounding competition, regulatory modifications, or other variables that might impact Teleflex's financial stability and market standing could be factoring into the current market sentiment.

22.00.2026 - TFX Stock was up 5.4%

• TFX stock experienced a strong bullish movement today despite recent negative developments and a 52-week low, possibly due to:
• Analysts' positive outlook on the company's return to profitability this year and its undervalued status.
• The announcement of the sale of three businesses for $2.03 billion and a $1 billion share repurchase program, signaling strategic moves to boost shareholder value.
• Investors may be optimistic about the company's future despite the CEO's exit, lower revenue outlook, and legal scrutiny, as evidenced by the stock's upward momentum.

12.01.2026 - TFX Stock was down 3.5%

• The bearish movement in Teleflex Inc. (TFX) today could be attributed to the sudden departure of CEO Liam Kelly, leading to governance and disclosure concerns among investors.
• The legal review initiated by Pomerantz LLP following the CEO exit may have raised apprehensions about potential securities violations or unlawful business practices, adding to the negative sentiment surrounding the stock.
• Despite the promising growth forecasts in the medtech sector, the uncertainty surrounding leadership and governance issues at Teleflex could have overshadowed the company's competitive edge and procedure-linked revenue prospects, resulting in the bearish market movement.

26.01.2026 - TFX Stock was up 10.1%

• The recent upward trend in TFX may be linked to expectations of favorable Q4 earnings, with analysts forecasting a 15.9% increase in revenue compared to the previous year.
• Despite being tagged as overvalued by a DCF analysis, the company's lower valuation in relation to its industry counterparts based on the Price/Sales ratio could be drawing investor interest.
• Although brokerages have given TFX an average "Hold" rating, the optimism surrounding potential earnings and the strong performance of industry peers could be bolstering confidence among investors.
• The recent announcement of new leadership at MassMEDIC, a notable development in the medical device sector, is not directly tied to TFX's recent positive movement.

18.01.2026 - TFX Stock was up 5.0%

• Teleflex hosting a conference call to discuss its Q4 2025 financial results and operational updates likely generated positive investor sentiment and confidence in the company's performance.
• The increase in stake by the Public Sector Pension Investment Board and other institutional investors, despite the stock trading near its 1-year low, indicates growing interest and belief in the long-term potential of Teleflex.
• Teleflex's recognition as a "Quiet Medtech Workhorse" powering the future of minimally invasive care highlights the company's strong position in the market, attracting investors looking for reliable revenue streams and innovative healthcare solutions.
• Overall, the bullish movement in Teleflex's stock today can be attributed to the positive outlook surrounding the company's financial performance, strategic positioning in the healthcare industry, and investor confidence in its long-term growth prospects.

19.01.2026 - TFX Stock was up 6.1%

• The bullish movement in TFX today could be attributed to anticipation surrounding the upcoming Q4 2025 earnings call and the potential positive outcomes from the company's strategic shift and divestment of businesses.
• The increased stake in TFX by institutional investors, such as the Public Sector Pension Investment Board, might have also contributed to the positive market sentiment, signaling confidence in the company's future prospects.
• Investors are likely optimistic about the company's commitment to innovation in healthcare and are closely monitoring any updates on capital allocation plans, including the share repurchase program, which could further boost shareholder value.

27.02.2026 - TFX Stock was up 5.1%

• Despite industry challenges and regulatory scrutiny, Teleflex Inc. (TFX) experienced a significant bullish movement today.
• Investor confidence in the company's innovation, global presence, and cost management likely supported this positive trend.
• Optimism about potential recovery in hospital spending and strategic plans, such as a potential split, may have contributed to the market optimism.
• Despite trailing behind competitors, consecutive days of stock gains indicate growing positive sentiment and long-term potential interest from investors.

27.02.2026 - TFX Stock was up 5.1%

• Recent investor interest in Teleflex Inc. (TFX) has been driven by encouragement from activist investor, Irenic Capital Management, for the company to explore acquisition offers, potentially boosting optimism regarding its strategic decisions.
• Despite challenges such as constrained hospital budgets and FDA product reviews, Teleflex's commitment to innovation and cost efficiencies has resonated positively with investors, contributing to its strong stock performance.
• TFX stock has seen consecutive gains while the broader market faced challenges, signaling investor confidence in the company's ability to overcome industry obstacles and seize growth prospects.
• Although TFX stock has shown daily advances, its relative underperformance compared to peers suggests lingering investor concerns about competitive positioning and market dynamics that warrant close observation.

14.03.2026 - TFX Stock was up 5.1%

• Teleflex stock saw a 4.05% increase today, surpassing its competitors and the overall market.
• The surge in stock value is believed to be linked to an upgrade by Bank of America from 'underperform' to 'neutral', setting a price target of $135, indicating a more favorable outlook for the company.
• Recent governance changes, adjustments to the company's portfolio, and improved earnings visibility resulting from buybacks and debt reduction have all played a role in the stock's upward movement.
• Despite falling short of Q4 earnings predictions and a decrease in revenue, Teleflex's strategic actions and positive analyst feedback have boosted investor confidence, leading to the strong performance witnessed today.